RedHill Biopharma’s Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue – BioSpace
RedHill Biopharma’s COVID-19 Phase 2/3 study of opaganib passes fourth DSMB review with unanimous recommendation to continue BioSpace
Comments are closed.